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Almost 50% of all Helicobacter pylori isolates are resistant to metronidazole, which reduces the
efficacy of metronidazole-containing regimens, but does not make them completely ineffective. This
discrepancy between in vitro metronidazole resistance and treatment outcome may partially be
explained by changes in oxygen pressure in the gastric environment, as metronidazole-resistant
(MtzR) H. pylori isolates become metronidazole-susceptible (MtzS) under low oxygen conditions in
vitro. InH. pylori the rdxA and frxA genes encode reductases which are required for the activation of
metronidazole, and inactivation of these genes results in metronidazole resistance. Here the role of
inactivating mutations in these genes on the reversibility of metronidazole resistance under low
oxygen conditions is established. Clinical H. pylori isolates containing mutations resulting in a
truncated RdxA and/or FrxA protein were selected and incubated under anaerobic conditions, and
the effect of these conditions on the MICs of metronidazole, amoxycillin, clarithromycin and
tetracycline, and cell viability were determined. While anaerobiosis had no effect on amoxycillin,
clarithromycin and tetracycline resistance, all isolates lost their metronidazole resistance when
cultured under anaerobic conditions. This loss of metronidazole resistance also occurred in the
presence of the protein synthesis inhibitor chloramphenicol. Thus, factor(s) that activate
metronidazole under low oxygen tension are not specifically induced by low oxygen conditions, but
are already present undermicroaerophilic conditions. As therewere no significant differences in cell
viability between the clinical isolates, it is likely that neither the rdxA nor the frxA gene participates in
the reversibility of metronidazole resistance.
INTRODUCTION
Helicobacter pylori is a spiral-shaped, Gram-negative bacter-
ium that colonizes the stomach of approximately half the
world’s population (Blaser & Berg, 2001). Colonization with
H. pylori is the most common cause of chronic active gastritis
and peptic ulcer disease, and is strongly associated with the
development of gastric cancer and gastric lymphoma. Unless
treated with antibiotics, H. pylori colonization tends to
persist for life. Cure of H. pylori infection results in ulcer
healing and may reduce the risk of gastric cancer and gastric
lymphoma development (Sugiyama et al., 2002; Wilhelmsen
& Berstad, 1994). In vitro, H. pylori is susceptible to the
majority of antibiotics, but for effective treatment a combi-
nation of drugs is required (Debets-Ossenkopp et al., 1999b).
Currently used anti-H. pylori therapies often consist of two
antibiotics with a proton pump inhibitor and/or a bismuth
component (Malfertheiner et al., 2002). Metronidazole [1-
(2-hydroxyethyl)-2-methyl-5-nitroimidazole] is a key com-
ponent of such combination therapies (Malfertheiner et al.,
2002; van der Hulst et al., 1996).
In Western Europe it has been estimated that 20–45 % of the
H. pylori isolates are metronidazole-resistant (MtzR)
(Glupczynski et al., 2001; Lopez-Brea et al., 2001). This
percentage is even higher in developing countries and
immigrant populations (Falsafi et al., 2004; Loffeld & Fijen,
2003). Although there are conflicting reports concerning the
clinical relevance of metronidazole resistance in H. pylori,
metronidazole resistance reduces the efficacy of metronida-
Abbreviations: MtzR , metronidazole-resistant; RAPD, random amplified
polymorphic DNA.
The GenBank accession numbers for the rdxA and frxA gene sequences
of seven metronidazole-resistant H. pylori strains are AY568322–
AY568328 and AY568330–AY568336.
zole-containing regimens significantly (Jenks et al., 1999a;
van der Wouden et al., 1999), but surprisingly does not
render them inactive.
Metronidazole is a prodrug that needs to be activated by a
reduction of the nitro group that is attached to the imidazole
ring. This reduction step leads to the production of DNA-
damaging nitroso- and hydroxylamine-compounds. Expo-
sure to these toxic compounds causes DNA damage, and
subsequently results in the death of the bacterium. In H.
pylori, it is believed that reduction of metronidazole is mainly
mediated by an oxygen-insensitive NADPH nitroreductase
(RdxA) (Goodwin et al., 1998; Sisson et al., 2002), but
recently it has been shown that the NADPH-flavin-oxido-
reductase (FrxA) also participates in the reduction of
metronidazole (Jeong et al., 2000).
In H. pylori, metronidazole resistance is primarily associated
with mutational inactivation of the rdxA gene (Debets-
Ossenkopp et al., 1999a; Goodwin et al., 1998; Jenks et al.,
1999b). However, recently it has been demonstrated that
inactivation of the frxA gene also confers metronidazole
resistance, either alone or in association with the rdxA gene
(Jeong et al., 2000; Kwon et al., 2000a, b, 2001). Whether
mutational inactivation of these two enzymes accounts for
metronidazole resistance in all clinical isolates is still being
debated (Bereswill et al., 2003; Chisholm & Owen, 2004;
Kwon et al., 2000a), but they most likely reflect the two major
contributing factors.
The discrepancy between the in vitro resistance to metroni-
dazole and treatment outcome may be explained by the
antimicrobial activity of other components in the regimens
and/or duration and doses of the therapy (van der Wouden et
al., 1999). Apart from these factors, it is likely that low oxygen
tension in the gastric environment may also be involved
(Smith & Edwards, 1995), since low oxygen conditions affect
the activity of metronidazole-reducing enzymes (Jenks &
Edwards, 2002). As in vitro MtzR H. pylori isolates become
susceptible to metronidazole after a short period of anaerobic
incubation (Cederbrant et al., 1992; Smith & Edwards, 1995),
it has been suggested that the FrxA protein and/or other
ferredoxin and flavin reductases may contribute to the
activation of metronidazole under these conditions
(Goodwin et al., 1998; Kaihovaara et al., 1998).
In this study the role of null mutations in the rdxA and frxA
genes on the reversibility of metronidazole resistance under
low oxygen conditions was determined.
METHODS
Strains and growth conditions. H. pylori isolates used in this study
and their respective rdxA and frxA gene status inferred from DNA
sequences are listed in Table 1. The H. pylori isolates were routinely
grown on Dent plates as described previously (Gerrits et al., 2002b).
Broth cultures were grown in Brucella broth supplemented with 3 %
newborn calf serum (BBN). All cultures were incubated either under
microaerophilic (5 % O2, 10 % CO2 and 85 % N2) or anaerobic
conditions (10 % H2, 5 % CO2 and 85 % N2) at 37 8C. The anaerobic
culture condition was created using the Anoxomat (Mart) in combina-
tion with a catalyst. Escherichia coli strain DH5Æ MCR (Life Technol-
ogies) was grown on Luria–Bertani agar plates (Sambrook et al., 1989)
for 24 h at 37 8C in an aerobic environment. Selection of E. coli
transformed with pGEM-T Easy clones was performed on LB-agar
plates containing ampicillin to a final concentration 100 g ml1
(Sigma-Aldrich).
DNAmanipulation.DNA manipulations were performed according to
standard protocols (Sambrook et al., 1989). Oligonucleotides (Table 2;
Isogen), PCR-core system I (Promega) and pGEM-T Easy vector
(Promega) were used according to the manufacturer’s recommenda-
tions. Plasmid DNA was isolated with Wizard Plus SV Minipreps DNA
Purification System (Promega) according to the manufacturer’s in-
Table 1. MtzR H. pylori strains and their rdxA and frxA gene status
H. pylori isolate MIC (gml21)* GenBank accession no.
rdxA (HP0954) frxA (HP0642)
Truncated rdxA gene
BH9711-176 24 AY568322 AY568330
DM9735-58 .256 AY568328 AY568336
Truncated frxA gene
BH9713-141 .256 AY568323 AY568331
DM9642-108 .256 AY568325 AY568333
DM9716-140 32 AY568326 AY568334
Truncated rdxA and frxA genes
BH9714-19 128 AY568324 AY568332
DM9727-179 192 AY568327 AY568335
ATCC 43504T .256 Debets-Ossenkopp et al. (1999a) Kwon et al. (2000b)
*MICs shown are means of results from three independent experiments. The isolates were considered to be
resistant when the MIC of metronidazole was >8 g ml1 (Gerrits et al., 2002b).
M. M. Gerrits and others
1124 Journal of Medical Microbiology 53
structions. Sequencing of the obtained plasmid and PCR products was
performed by Baseclear (Leiden, The Netherlands).
RandomamplifiedpolymorpicDNA (RAPD)fingerprinting.RAPD
analysis of chromosomal DNA was performed with three independent
primers, 1254, D11344 and D9355 as described before by Akopyanz et al.
(1992). RAPD products were separated in 2 % agarose gels containing
0.5 g ethidium bromide ml1 (Promega).
The influence of the length of anaerobic incubation on antibiotic
resistance. MIC values were routinely analysed by E-test (AB Biodisk)
(Gerrits et al., 2002b) or agar dilution (Trieber & Taylor, 2002). The
plates were incubated under anaerobic conditions for 0, 0.25, 0.5, 1, 2, 4
and 8 h and subsequently incubated for 3 days at 37 8C under
microaerophilic conditions, according to the guidelines of the National
Committee for Clinical Laboratory Standards. The isolates were con-
sidered resistant when the MICs of amoxycillin >8 g ml1, clarithro-
mycin >2 g ml1, metronidazole >8 g ml1and tetracycline >4 g
ml1 (Gerrits et al., 2002b). As controls, resistant strains were included
for each tested antibiotic (Debets-Ossenkopp et al., 1998; Gerrits et al.,
2002a, b). All MIC determinations were performed in triplicate.
The influence of chloramphenicol on metronidazole resistance
during anaerobic incubation. Bacteria freshly grown on Dent plates
were harvested and inoculated in BBN to a cell density of13107 c.f.u.
ml1, and incubated overnight with gentle agitation under microaer-
ophilic conditions. Fumaric acid (Sigma-Aldrich, final concentration
0.1 %) was then added to the overnight culture to facilitate the
generation of anaerobic conditions (Jenks et al., 1999b). The culture
was then split into 10 ml portions and when indicated supplemented
with metronidazole (Sigma-Aldrich, final concentration 16 g ml1)
and/or chloramphenicol (Sigma-Aldrich, final concentration 10 g
ml1). Subsequently, the cultures were incubated under microaerophi-
lic or anaerobic conditions for 0, 2, 4, 6 and 8 h. At each time point 1 ml
of the broth was taken and washed twice with PBS to remove the
antibiotics. In order to determine the number of viable bacteria, 50 l of
undiluted suspension and 101, 102, 103 and 104 dilutions were
plated on Columbia agar plates containing 7 % lysed horse blood and
incubated under microaerophilic conditions. When present, colonies
were counted and data are expressed as c.f.u. ml1.
RESULTS AND DISCUSSION
Effect of anaerobic incubation on MIC
To evaluate the effect of anaerobic incubation on the MIC of
metronidazole, seven MtzR H. pylori clinical isolates and the
MtzR H. pylori reference strain ATCC 43504T were selected
for this study. To ensure that these strains represented
different isolates, RAPD fingerprinting was performed with
primers D11344 (Fig. 1), 1254 and D9355 (data not shown).
All strains gave different profiles with each of the three
primers, indicating they represent unrelated isolates. These
seven MtzR isolates and reference strain ATCC 43504T were
incubated in microaerophilic and anaerobic conditions, and
the MIC of metronidazole was determined by E-test and agar
dilution. Under standard microaerophilic culture condi-
tions, the MIC of metronidazole for the eight isolates, as
determined by E-test, ranged from 24 to .256 g ml1,
(Table 3). These MICs for metronidazole decreased under
anaerobic conditions. After 4 h of anaerobic incubation, the
MIC values for metronidazole dropped below the breakpoint
(8 g ml1) for three of the eight isolates, and after 8 h, all
MtzR isolates had become metronidazole-susceptible (Table
3). In contrast to metronidazole, the MICs for amoxycillin,
clarithromycin and tetracycline were stable during anaerobic
incubation (data not shown). There were no clear differences
found in the MIC values between the E-test and agar dilution.
Effect of metronidazole and anaerobic incubation
on cell viability
To determine the effect of metronidazole and anaerobic
incubation on cell viability, all seven MtzR H. pylori isolates
and the MtzR reference strain ATCC 43504T were cultured in
broth under microaerophilic and anaerobic conditions
Table 2. Oligonucleotides used in this study
Oligonucleotides used for amplification were based on the published
genome sequence of H. pylori strain 26695 (Tomb et al., 1997).
Gene/primer
name
Nucleotide sequence (59 39)
rdxA (HP0954)
RdxA-F1 GCTGATTGTGGTTTATGGTTTGG
RdxA-F2 TTGGATCAAGAAAAAAGAAGACAATTATTAA
RdxA-F3 GCTGATTGTGGTTTATGGTTTGG
RdxA-F4 GAGAGCCGGACAGCCAAATG
RdxA-R1 CACCCCTAAAAGAGCGATTAAAACC
RdxA-R2 GCAAGAATGGCGCTCGTT
RdxA-R3 CCCACAGCGATATAGCATTG
frxA (HP0642)
FrxA-F1 GGATATGGCAGCCGTTTATCATT
FrxA-R1 GAATAGGCATCATTTAAGAGATTA
FrxA-R2 TGGTTCAAGCCCGATTGAAG
!
Fig. 1. The H. pylori isolates used in this study represent unrelated
isolates, as shown by RAPD-PCR. DNA isolated from the MtzR isolates
was amplified with primer D11344 according to standard procedures
(Akopyanz et al., 1992). The RAPD-PCR products were separated on
a 2.0 % agarose gel and stained with ethidium bromide. Lane 1, H.
pylori reference strain ATCC 43504T, lanes 2–8, BH9711-176,
BH9713-141, BH9714-19, DM9735-58, DM9727-179, DM9642-
108 and DM9716-140, respectively. M, 1 kb marker (Promega).
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either in the presence or absence of 16 g metronidazole
ml1, and at different time intervals the amount of viable
bacteria (c.f.u. ml1) was determined. Under standard
microaerophilic conditions, the amount of viable cells for
all tested MtzR isolates varied between 106 and 107 c.f.u.
ml1, and there were no significant differences observed in
c.f.u. ml1 between the cultures with and without metroni-
dazole (Fig. 2). Similar data were obtained for the cultures
without metronidazole that were incubated anaerobically
(Fig. 2). This suggests that neither the incubation with
metronidazole nor anaerobic growth conditions alone affect
the cell viability of the MtzR isolates.
However, under anaerobic conditions in the presence of
metronidazole, the amount of viable cells dropped more than
1000-fold when the MtzR isolates were incubated for 4 h
anaerobically, and after 8 h of anaerobic incubation in the
presence of metronidazole there were no viable cells present
(Fig. 3). Since there were no differences in cell viability or
time-course observed between the MtzR isolates containing
mutations that resulted in either a truncated RdxA protein or
FrxA protein, or a truncation in both, this suggests that
neither the rdxA gene nor the frxA gene is involved in the
reversibility of metronidazole resistance in H. pylori.
Effect of de novo protein synthesis on reversibility
of metronidazole resistance during anaerobic
incubation
To determine whether H. pylori requires de novo protein
synthesis for the reversibility of metronidazole resistance, all
experiments were repeated in broth in the presence of the
bacterial protein synthesis inhibitor chloramphenicol (10 g
ml1). This concentration of chloramphenicol was opti-
mized previously, and its effects on the inhibition of the
protein synthesis and cell viability are known (Kusters et al.,
1997). When the MtzR isolates were incubated anaerobically
in the presence of metronidazole and chloramphenicol, cell
viability was reduced (Fig. 4). As there was no significant
difference in cell viability between the cultures with and
Table 3. The effect of anaerobic incubation on metronidazole
resistance
MICs shown are means of results from three independent experiments.
The isolates were considered to be resistant when the MIC of
metronidazole was >8 g ml1 (Gerrits et al., 2002b). T0, time point
zero, start point; T2, T4 and T8, after 2, 4 and 8 h of anaerobic incubation,
respectively.
H. pylori isolates MIC (gml21)
T0 T2 T4 T8
Truncated rdxA gene
BH9711-176 24 16 12 3
DM9735-58 .256 32 4 0.75
Truncated frxA gene
BH9713-141 .256 48 24 3
DM9642-108 .256 64 24 2
DM9716-140 32 8 4 0.75
Truncated rdxA and frxA genes
BH9714-19 128 48 12 4
DM9727-179 192 96 16 0.5
ATCC 43504T .256 48 6 0.25
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Fig. 2. The influence of metronidazole and anaerobic incubation on
cell viability. H. pylori was grown microaerophilically in the presence
(m) and absence (j) of 16 g metronidazole ml1, and anaerobically
(h). At different time points the c.f.u. ml1 was determined. Results
shown are a representative example of one of the MtzR isolates,
BH9714-19, and are the means (SD) of two independent experi-
ments performed in duplicate.
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Fig. 3. Involvement of the rdxA and/or frxA gene in the reversibility of
metronidazole resistance under anaerobic conditions. H. pylori was
grown in microaerophilic (filled symbols) and anaerobic (open sym-
bols) conditions in the presence of 16 g metronidazole ml1, and the
c.f.u. ml1 were determined. Results shown are for representative
examples of the MtzR isolates tested. j/h, BH9714-19 (containing
mutations resulting in truncated RdxA and FrxA proteins); m/n,
DM9735-58 (containing mutations resulting in a truncated RdxA);d/
s, BH9713-141 (containing mutations resulting in a truncated FrxA).
Results shown are the means (SD) of two independent experiments
performed in duplicate.
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without chloramphenicol these results indicate that factors
that are involved in the reversibility of metronidazole
resistance are already present under microaerophilic condi-
tions. De novo protein synthesis is not required for this
phenomenon.
Implications of experimental data
Metronidazole, a nitroimidazole, is administered as a pro-
drug that is activated by the reduction of the nitro group that
is attached to an imidazole ring (Edwards, 1986). Since
oxygen has a higher reduction potential than metronidazole,
this reduction step works out most effectively in an environ-
ment with low oxygen tension, such as anaerobic cells and
protozoa (Jenks & Edwards, 2002). Surprisingly, the drug
was also found to be active against the microaerophilic
pathogen H. pylori (Lacey et al., 1993). In many strictly
anaerobic bacteria, the activation of metronidazole is
mediated by the pyruvate : ferredoxin oxidoreductase com-
plex (Smith et al., 1998). In H. pylori, this function might be
fulfilled by the electron carriers, RdxA (HP0954), FrxA
(HP0642), ferredoxin (FdxA, HP0277), flavodoxin (FldA,
HP1161), pyruvate : ferredoxin oxidoreductase (PorD,
HP1109) and 2-oxoglutarate ferredoxin oxidoreductase
(OorD, HP0588). As mutations of the latter four nitro-
reductases were found to be lethal (Jeong et al., 2000; Kwon
et al., 2000a), we only tested the involvement of the rdxA and
frxA genes. In contrast with the findings under normal
microaerophilic conditions (Kwon et al., 2000b; Sisson et
al., 2002), we showed that neither the rdxA nor the frxA gene
is required for the activation of metronidazole under low
oxygen conditions, since strains with one or both genes
inactivated still become susceptible to metronidazole under
anaerobic conditions.
As MtzR H. pylori isolates lose their resistance to metronida-
zole after exposure to short periods of anaerobiosis in vitro
(Cederbrant et al., 1992; Smith & Edwards, 1995), it has been
suggested that this reversibility is mediated by compensatory
metabolic pathways that are induced under anaerobic con-
ditions (Jenks & Edwards, 2002; Smith & Edwards, 1997).
This hypothesis is not supported by our data obtained using
the protein synthesis inhibitor chloramphenicol. The loss of
metronidazole resistance is mediated by a pre-existing
mechanism that functions under anaerobic conditions, and
is not dependent on de novo protein synthesis when H. pylori
is exposed to these conditions. Since our data excluded the
role of the RdxA and FrxA proteins in this process, we assume
that in H. pylori metronidazole is reduced by one of the other
known nitroreductases.
In summary, MtzR H. pylori isolates become fully metroni-
dazole-susceptible at low oxygen conditions, and this does
not require de novo protein synthesis. This reversibility in
metronidazole resistance also occurred in H. pylori isolates
that contained mutations in the rdxA and/or frxA genes.
Exposure of H. pylori to such low oxygen conditions in the
gastric mucosa or gastric pit is likely to induce reduction of
metronidazole, and thus assist in the eradication of MtzR H.
pylori.
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